J 2020

Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation

KOJECKÝ, Vladimír, Jan MATOUS, Bohuslav KIANIČKA, Petr DITE, Zdena ZADOROVA et. al.

Basic information

Original name

Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation

Authors

KOJECKÝ, Vladimír (203 Czech Republic, belonging to the institution), Jan MATOUS (203 Czech Republic), Bohuslav KIANIČKA (203 Czech Republic, guarantor), Petr DITE (203 Czech Republic), Zdena ZADOROVA (203 Czech Republic), Jan KUBOVY (203 Czech Republic), Martina HLOSTOVA (203 Czech Republic) and Michal UHER (203 Czech Republic, belonging to the institution)

Edition

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, ABINGDON, TAYLOR & FRANCIS LTD, 2020, 0036-5521

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30219 Gastroenterology and hepatology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.423

RIV identification code

RIV/00216224:14110/20:00116133

Organization unit

Faculty of Medicine

DOI

UT WoS

000545392100001

Keywords in English

Inflammatory bowel disease; vitamin D deficiency; vitamin D intake; dietary supplements; body weight

Tags

Tags

International impact, Reviewed
Změněno: 31/8/2020 10:43, Mgr. Tereza Miškechová

Abstract

V originále

Objectives:Body weight is one of the factors affecting blood levels of 25-hydroxyvitamin D (25OHD). The aim of this study was to establish whether a vitamin D (vitD) weight-based dosing is more appropriate to a fixed daily dose in patients with inflammatory bowel disease (IBD). Materials/methods:This was an open label randomised trial. Patients with IBD were assigned to receive oral cholecalciferol at a dose of 28 IU/kg (IU/kg) or 2000 IU per day (IU/day) for 12 weeks during winter months. 25OHD plasma levels and other biochemical parameters were measured at baseline and after supplementation period. The primary outcome measure was 25OHD level after a follow-up period. Results:A total of 173 patients were analysed. The mean BMI was 25.5 +/- 5.1 and initial mean 25OHD level was 62.7 +/- 25.5 nmol/l. A similar increase (9.7 +/- 26.9 vs 9.8 +/- 26.7 nmol/l) in 25OHD levels occurred both in IU/kg and IU/day group. The proportion of subjects with normal and sub-normal levels following the substitution was comparable irrespective of body weight. The change in 25OHD level correlated positively only with the dose of vitD (p < .001) and negatively with the baseline 25OHD level (p < .001). A sustained 25OHD level of 75 nmol/l corresponds with a calculated daily vitD dose of 2034 IU. Conclusions:Weight-based dosing of vitamin D is not superior to a fixed dose in order to maintain stable 25OHD levels in IBD patients. Cholecalciferol dose of 2,000 IU/day is safe and sufficient during winter period.